Literature DB >> 34111963

Whole-body magnetic resonance imaging (WB-MRI) with diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) in prostate cancer: Prevalence and clinical significance of incidental findings.

Soma Kumasaka1, Shunichi Motegi2, Yuka Kumasaka1, Tatsuya Nishikata3, Masami Otomo3, Yoshito Tsushima1.   

Abstract

OBJECTIVE: Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) is now recommended as a first-line staging modality in prostate cancer patients, and the widespread use of DWIBS may lead to an increased frequency of incidental findings. The aim of this study was to evaluate the prevalence and clinical significance of incidental findings on whole-body magnetic resonance imaging (WB-MRI) with DWIBS.
METHODS: Data from 124 patients with prostate cancer (age, 76.5 ± 5.6 years), who underwent 1.5 T WB-MRI with STIR, TSE-T2, TSE-T1, In/Out GRE, and DWIBS sequences, were retrospectively analyzed. Findings unrelated to prostate cancer were considered as incidental findings and categorized into two groups based on their clinical implications as follows: imaging follow-up or additional examinations was required (significant incidental findings) and no need to additional work-up (non-significant incidental findings). A chi-square test was performed to compare the differences in the prevalence of significant incidental findings based on age (≤75 and>75 years old).
RESULTS: A total of 334 incidental findings were found with 8.1% (n = 27) as significant incidental findings. Significant incidental findings were more frequent in patients over 75 years old than those of 75 years old or younger (28.6% vs  11.1%, p = 0.018).
CONCLUSION: Clinically significant incidental findings, which required imaging follow-up or additional examinations, were commonly observed in prostate cancer patients on WB-MRI/DWIBS. ADVANCES IN KNOWLEDGE: Some incidental findings were clinically significant that may lead to changes in treatment strategy. Checking the entire organ carefully for abnormalities and reporting any incidental findings detected are important.

Entities:  

Mesh:

Year:  2021        PMID: 34111963      PMCID: PMC8978253          DOI: 10.1259/bjr.20210459

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  23 in total

1.  Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.

Authors:  Jacob L Jaremko; Peter J MacMahon; Martin Torriani; Vanessa L Merker; Victor F Mautner; Scott R Plotkin; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2011-12-07       Impact factor: 2.199

Review 2.  Overview of white papers of the ACR incidental findings committee ii on adnexal, vascular, splenic, nodal, gallbladder, and biliary findings.

Authors:  Lincoln L Berland
Journal:  J Am Coll Radiol       Date:  2013-06-28       Impact factor: 5.532

3.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?

Authors:  Frédéric E Lecouvet; Jawad El Mouedden; Laurence Collette; Emmanuel Coche; Etienne Danse; François Jamar; Jean-Pascal Machiels; Bruno Vande Berg; Patrick Omoumi; Bertrand Tombal
Journal:  Eur Urol       Date:  2012-02-17       Impact factor: 20.096

4.  Whole-body MRI in patients with lymphoma: collateral findings.

Authors:  Massimo Galia; Domenico Albano; Donatella Narese; Caterina Patti; Vito Chianca; Francesco Di Pietto; Antonino Mulè; Emanuele Grassedonio; Ludovico La Grutta; Roberto Lagalla; Massimo Midiri
Journal:  Radiol Med       Date:  2016-06-15       Impact factor: 3.469

Review 5.  The economic burden of incidentally detected findings.

Authors:  Alexander Ding; Jonathan D Eisenberg; Pari V Pandharipande
Journal:  Radiol Clin North Am       Date:  2011-03       Impact factor: 2.303

6.  Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study.

Authors:  A Stecco; G Romano; M Negru; D Volpe; A Saponaro; S Costantino; G Sacchetti; E Inglese; O Alabiso; A Carriero
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

7.  Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images.

Authors:  Katsuyuki Nakanishi; Midori Kobayashi; Kazunori Nakaguchi; Miyaji Kyakuno; Nobuyuki Hashimoto; Hiromitsu Onishi; Noboru Maeda; Saki Nakata; Masatomo Kuwabara; Takamichi Murakami; Hironobu Nakamura
Journal:  Magn Reson Med Sci       Date:  2007       Impact factor: 2.471

8.  Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images.

Authors:  Yoshito Tsushima; Akie Takano; Ayako Taketomi-Takahashi; Keigo Endo
Journal:  Acad Radiol       Date:  2007-06       Impact factor: 3.173

9.  Incidental findings in healthy control research subjects using whole-body MRI.

Authors:  S H X Morin; J F L Cobbold; A K P Lim; J Eliahoo; E L Thomas; S R Mehta; G Durighel; J Fitzpatrick; J D Bell; S D Taylor-Robinson
Journal:  Eur J Radiol       Date:  2008-09-24       Impact factor: 3.528

10.  Non-contrast-enhanced whole-body magnetic resonance imaging in the general population: the incidence of abnormal findings in patients 50 years old and younger compared to older subjects.

Authors:  Andrzej Cieszanowski; Edyta Maj; Piotr Kulisiewicz; Ireneusz P Grudzinski; Karolina Jakoniuk-Glodala; Irena Chlipala-Nitek; Bartosz Kaczynski; Olgierd Rowinski
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

View more
  2 in total

1.  Innovations in prostate cancer: introductory editorial.

Authors:  Jurgen J Fütterer; Chan Kyo Kim; Daniel J Margolis
Journal:  Br J Radiol       Date:  2022-03       Impact factor: 3.039

Review 2.  Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI.

Authors:  Durgesh Kumar Dwivedi; Naranamangalam R Jagannathan
Journal:  MAGMA       Date:  2022-07-22       Impact factor: 2.533

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.